Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
small EV-PH20
- Development stage
- Preclinical
- Lead developer
- ShiftBio
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral, Intravenous
01
Overview
small EV-PH20 (also known as Exo-PH20) is a preclinical-stage engineered exosome (small extracellular vesicle) displaying GPI-anchored PH20 hyaluronidase on its surface. Developed by ShiftBio and originally researched at the Korea Institute of Science and Technology (KIST), the therapeutic candidate is designed to degrade high-molecular-weight hyaluronan (HA) within the tumor extracellular matrix. By breaking down this physical barrier, small EV-PH20 enhances the penetration of therapeutic agents and immune cells into the tumor microenvironment. Additionally, the resulting low-molecular-weight hyaluronan fragments stimulate the maturation and migration of CD103+ dendritic cells, boosting tumor-specific CD8+ T-cell responses. In preclinical studies, small EV-PH20 has been evaluated in combination with PD-L1 blockade to synergistically enhance antitumor immunity and inhibit tumor growth in cancer models.
- Other names
- Exo-PH20Exo-PH-20Exo-PH 20sEV-PH20sEV-PH-20sEV-PH 20small extracellular vesicle displaying PH20small extracellular vesicle-PH20
Beyond the preview
Go deeper on small EV-PH20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on small EV-PH20.